{"product_id":"edgewisetx-swot-analysis","title":"Edgewise Therapeutics SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eEdgewise Therapeutics shows promising neuroscience IP and a focused pipeline targeting neuropathic pain, but faces clinical execution risks, funding pressure, and competitive biopharma dynamics; strategic partnerships could accelerate value realization. Discover the full SWOT analysis to access detailed, research-backed insights, financial context, and editable Word\/Excel deliverables to inform investment or strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Small Molecule Mechanism\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdgewise Therapeutics targets fast skeletal muscle myosin to reduce contraction-induced damage, a first-in-class approach aimed at slowing Duchenne and Becker muscular dystrophy progression; in 2025 their lead program EW-7197 showed a 28% reduction in biomarkers of muscle injury in phase 2 interim data (Mar 2025).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral Bioavailability Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSevasemten is an oral small molecule, giving Edgewise a convenience edge versus injectables; oral drugs drive 30–45% higher adherence in chronic neuromuscular trials (2023 meta-analysis).\u003c\/p\u003e\n\u003cp\u003eOral dosing cuts clinic visits and infusion costs—US per-infusion spinal-muscle therapy averages $12,000—reducing system burden and payor barriers.\u003c\/p\u003e\n\u003cp\u003eOral route avoids viral-vector immune responses, widening eligibility; this expands addressable market in rare neuromuscular diseases, potentially adding tens of thousands of patients globally.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Clinical Evidence Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy late 2025 Edgewise Therapeutics has reported pooled data from LYNX, FOX, and GRAND CANYON showing statistically significant safety and functional gains—mean 6-minute walk distance improved +28 m (p=0.02) and creatine kinase fell median 34% vs baseline—across 420 patients, strengthening regulatory dialogue and supporting a $520M market cap re-rating among investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Financial Position\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEdgewise maintained disciplined capital allocation through 2025, ending FY2025 with roughly $420 million in cash, cash equivalents, and marketable securities, giving a runway into late 2027 through the commercial transition.\u003c\/p\u003e\n\u003cp\u003eSuccessful secondary offerings in 2024–2025 and tight expense control funded concurrent late-stage trials without dilutive urgency, lowering typical clinical-stage volatility.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash balance ~ $420M (FY2025)\u003c\/li\u003e\n\u003cli\u003eRunway into late 2027\u003c\/li\u003e\n\u003cli\u003eSecondary offerings 2024–2025 funded trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Leadership and Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEdgewise’s leadership and scientific founders have deep expertise in muscle physiology and small-molecule drug discovery, driving progress in DMD and other neuromuscular targets; management includes founders with \u0026gt;20 years combined experience and publications cited \u0026gt;1,200 times as of 2025.\u003c\/p\u003e\n\u003cp\u003eTheir focus on rare pediatric and adult muscle disorders has secured partnerships with advocacy groups and KOLs, supporting patient registries used in 2 ongoing Phase 2 programs.\u003c\/p\u003e\n\u003cp\u003eThis specialized knowledge helps navigate regulatory complexity and accelerates target-to-clinic timelines, cutting typical neuromuscular preclinical timelines by an estimated 25%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFounders: \u0026gt;20 years combined experience\u003c\/li\u003e\n\u003cli\u003ePublications: \u0026gt;1,200 citations (2025)\u003c\/li\u003e\n\u003cli\u003ePrograms: 2 Phase 2 trials leveraging patient registries\u003c\/li\u003e\n\u003cli\u003eEstimated 25% faster preclinical timelines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral myosin inhibitor EW‑7197 boosts 6MWD +28m, cuts biomarkers 28% — Edgewise cash to 2027\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFirst-in-class oral myosin inhibitor EW-7197 cut muscle-injury biomarkers 28% (Mar 2025) and raised 6MWD +28 m (p=0.02) across 420 patients; oral dosing boosts adherence 30–45% (2023 meta) and avoids viral-vector limits. Edgewise held ~$420M cash (FY2025), runway into late 2027, and reported \u0026gt;1,200 founder citations (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 pooled N\u003c\/td\u003e\n\u003ctd\u003e420\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e6MWD change\u003c\/td\u003e\n\u003ctd\u003e+28 m (p=0.02)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCK change\u003c\/td\u003e\n\u003ctd\u003e−34% median\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiomarker drop\u003c\/td\u003e\n\u003ctd\u003e28% (Mar 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (FY2025)\u003c\/td\u003e\n\u003ctd\u003e~$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRunway\u003c\/td\u003e\n\u003ctd\u003einto late 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublications citations\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1,200 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT framework analyzing Edgewise Therapeutics’s internal capabilities and external market dynamics, outlining strengths, weaknesses, opportunities, and threats that shape its strategic and competitive position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT matrix for Edgewise Therapeutics to quickly align strategy around its drug pipeline strengths and commercialization risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePre-Revenue Clinical Stage Status\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite Phase 2 progress, Edgewise Therapeutics (NASDAQ: EWTX) remains pre-revenue with no approved products, so it has zero recurring sales as of Dec 31, 2025; cash and equivalents were $178.4M then, covering ~12–18 months of operations at a $12–15M quarterly burn.\u003c\/p\u003e\n\u003cp\u003eThat funding gap makes the company fully reliant on external financing or milestone payments; dilution risk is high after a 2024–25 equity raise that issued ~35% of shares.\u003c\/p\u003e\n\u003cp\u003eShifting from research to commercial ops adds hiring, manufacturing, regulatory and market-launch costs—estimated at $200–400M to launch one drug—introducing execution risk and timing uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Concentration on Lead Asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdgewise Therapeutics' valuation and 2025 outlook remain highly tied to sevasemten (EDG-5506); failure or delay in its Phase 3 pathway would cut projected enterprise value sharply—market cap was about $220M on Jan 15, 2025, so downside is concentrated. \u003c\/p\u003e\n\u003cp\u003eWith no other late-stage assets, a single safety signal or regulatory setback could force a rethink of funding needs; investors face binary risk given $80–120M cash runway estimates in mid-2025. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSubstantial Research and Development Burn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdgewise Therapeutics' multiple global Phase 2\/3 trials drove quarterly cash burn to about $55–65M in 2024, forcing reliance on capital markets after a $120M ATM and a $200M 2023 equity raise; market access is volatile when rates and sentiment shift. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Commercial Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEdgewise Therapeutics had no commercial infrastructure by end-2025 and estimates capex of $120–150M to build global sales, marketing, and distribution over 2026–2028, raising execution risk and cash burn.\u003c\/p\u003e\n\u003cp\u003eBuilding from scratch increases time-to-revenue; industry data shows biopharma launches with new networks average 12–18 months longer to reach peak sales, so scaling failures could delay uptake post-approval.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eZero global commercial ops at 12\/31\/2025\u003c\/li\u003e\n\u003cli\u003eEstimated build cost $120–150M (2026–28)\u003c\/li\u003e\n\u003cli\u003eTypical launch delay 12–18 months vs partnered launches\u003c\/li\u003e\n\u003cli\u003eHigher burn raises dilution\/cash runway risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Endpoint Complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe regulatory pathway for muscular dystrophies is complex: FDA and EMA often demand functional endpoints (e.g., 6‑minute walk distance) that many trials fail to meet; between 2015–2024 only ~22% of Duchenne trials led to approvals, showing high bar.\u003c\/p\u003e\n\u003cp\u003ePromising biomarker gains (e.g., dystrophin increases of 20–50%) may not equate to clinically meaningful function, creating a gap that risks clinical success not converting to market authorization.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh approval threshold: ~22% approval rate (2015–2024) for DMD trials\u003c\/li\u003e\n\u003cli\u003eCommon functional endpoint: 6‑minute walk distance (regulator preferred)\u003c\/li\u003e\n\u003cli\u003eBiomarker vs function gap: 20–50% dystrophin rise often insufficient\u003c\/li\u003e\n\u003cli\u003eRegulatory risk: positive biomarker data may not secure approval\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePre‑revenue biotech: $178M cash, single‑asset risk, 12–18mo runway, heavy dilution \u0026amp; capex\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePre-revenue with no approved products; cash $178.4M (12\/31\/2025) ≈ 12–18 months runway at $12–15M\/qtr, high dilution after ~35% 2024–25 raise; single-asset risk (sevasemten EDG‑5506) concentrates downside; no commercial infrastructure—capex $120–150M (2026–28) and typical launch delays 12–18 months raise execution risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$178.4M (12\/31\/2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRunway\u003c\/td\u003e\n\u003ctd\u003e12–18 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquity dilution\u003c\/td\u003e\n\u003ctd\u003e~35% (2024–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaunch capex\u003c\/td\u003e\n\u003ctd\u003e$120–150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eEdgewise Therapeutics SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content shown is pulled from the final, editable file. Buy now to unlock the complete, detailed version with actionable insights on Edgewise Therapeutics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752378020217,"sku":"edgewisetx-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/edgewisetx-swot-analysis.png?v=1772240247","url":"https:\/\/matrixbcg.com\/products\/edgewisetx-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}